CHEMOMAB THERAPEUTICS LTD's ticker is CMMB and the CUSIP is 16385C104. A total of 14 filers reported holding CHEMOMAB THERAPEUTICS LTD in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $458 | -50.3% | 288,169 | 0.0% | 0.03% | -51.6% |
| Q4 2022 | $922 | -99.9% | 288,169 | 0.0% | 0.06% | +24.0% |
| Q3 2022 | $718,000 | -32.6% | 288,169 | +0.0% | 0.05% | -38.3% |
| Q2 2022 | $1,066,000 | -22.9% | 288,168 | 0.0% | 0.08% | -23.6% |
| Q1 2022 | $1,383,000 | – | 288,168 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,578,174 | $12,375,000 | 0.20% |
| Ikarian Capital, LLC | 268,104 | $1,292,000 | 0.17% |
| Cormorant Asset Management, LP | 288,168 | $1,383,000 | 0.11% |
| BOOTHBAY FUND MANAGEMENT, LLC | 41,298 | $198,000 | 0.01% |
| MEITAV INVESTMENT HOUSE LTD | 35,024 | $167,000 | 0.00% |
| Newbridge Financial Services Group, Inc. | 1,100 | $5,000 | 0.00% |
| ENVESTNET ASSET MANAGEMENT INC | 10,807 | $52,000 | 0.00% |
| JPMORGAN CHASE & CO | 753 | $4,000 | 0.00% |
| Renaissance Technologies | 27,960 | $134,000 | 0.00% |
| ARK Investment Management | 792 | $4,000 | 0.00% |